Just Released: "Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022"

GlobalData has released its new PharmaPoint Drug Evaluation report, "Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients' survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Teva's Synribo (omacetaxine mepesuccinate) is a chemotherapy for the treatment of CP or AP CML that is resistant to prior therapy with multiple TKIs. Synribo was originally developed by ChemGenex, which was bought by Cephalon in 2011, and is now a subsidiary of Teva. The MOA of Synribo has not been conclusively established; however, the drug has been shown to inhibit protein synthesis (Synribo Prescribing Information, 2012). Unlike its competitors, Synribo does not directly target BCR-ABL, although it did reduce in vitro levels of BCR-ABL and the anti-apoptotic proteins BCL-2 and MTL-1.

Full Report Details at
- http://www.fastmr.com/prod/608215_synribo_chronic_myeloid_leukemia_forecast_and.aspx?afid=303

Scope

* Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Synribo including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Synribo for the top seven countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for CML
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Synribo performance
* Obtain sales forecast for Synribo from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022
- EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022